Twenty-four seven
7074
Alpico Holdings
297A
Branding Technology
7067
Estore
4304
Axel Mark
3624
JP Stock MarketDetailed Quotes
4893 Noile-Immune Biotech
- 159
- +1+0.63%
20min DelayMarket Closed Dec 27 15:30 JST
6.88BMarket Cap-5.83P/E (Static)
160High156Low155.50KVolume159Open158Pre Close24.53MTurnover35352wk High1.16%Turnover Ratio43.30MShares12152wk Low-22.01EPS TTM2.12BFloat Cap775Historical HighLossP/E (Static)13.36MShs Float121Historical Low-27.25EPS LYR2.53%Amplitude--Dividend TTM1.38P/B100Lot Size--Div YieldTTM
Noile-Immune Biotech Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|
| Operating cash flow (Indirect Method) | ||||
| Cash from operating activities | -728.14%-870.7M | 86.47%-105.14M | -69.70%-776.84M | -457.78M |
| Net profit before non-cash adjustment | -193.49%-1.13B | 51.53%-384.2M | -25.62%-792.62M | ---630.97M |
| Total adjustment of non-cash items | 40.08%352.28M | 2,467.57%251.48M | -119.58%-10.62M | --54.26M |
| -Depreciation and amortization | ---- | ---- | --0 | --12.81M |
| -Reversal of impairment losses recognized in profit and loss | ---- | ---- | --0 | --26.36M |
| -Disposal profit | --0 | --0 | --0 | ---- |
| -Net exchange gains and losses | 109.56%440K | ---4.6M | --0 | ---- |
| -Other non-cash items | 37.39%351.84M | 2,510.88%256.08M | -170.40%-10.62M | --15.09M |
| Changes in working capital | -445.86%-95.39M | 4.47%27.58M | -77.80%26.4M | --118.94M |
| -Change in receivables | -233.00%-70.54M | 5,038.27%53.04M | -100.58%-1.07M | --185.59M |
| -Change in inventory | -5,034.59%-16.98M | -95.17%344K | 171.05%7.12M | ---10.02M |
| -Change in prepaid assets | 90.80%-2.37M | -214.49%-25.8M | 227.54%22.54M | ---17.67M |
| -Change in payables | 59.05%-3.46M | -131.36%-8.44M | 280.07%26.91M | ---14.95M |
| -Change in accrued expense | -100.47%-45K | 250.09%9.62M | -53.06%2.75M | --5.85M |
| -Changes in other current assets | -70.36%-2M | 96.31%-1.17M | -6.62%-31.84M | ---29.86M |
| Dividends paid (cash flow from operating activities) | ||||
| Dividends received (cash flow from operating activities) | ||||
| Interest paid (cash flow from operating activities) | ||||
| Interest received (cash flow from operating activities) | 16.22%43K | 27.59%37K | 61.11%29K | 18K |
| Tax refund paid | -0.67%-2.42M | -617.61%-2.4M | -100.21%-335K | 157.11M |
| Other operating cash inflow (outflow) | -100.61%-2K | 16,400.00%330K | 0.00%2K | 2K |
| Operating cash flow | -714.62%-873.08M | 86.21%-107.18M | -158.49%-777.14M | ---300.65M |
| Investing cash flow | ||||
| Net changes in other investments | ---5.32M | ---- | ---4.03M | ---- |
| Investing cash flow | ---5.32M | --0 | ---4.03M | --0 |
| Financing cash flow | ||||
| Net common stock issuance | 403.30%2.51B | -79.01%498.32M | 138.24%2.37B | --996.35M |
| Issuance fees | -4,644.83%-594.95M | ---12.54M | --0 | ---- |
| Net other fund-raising expenses | ---- | --1.84M | ---- | ---- |
| Financing cash flow | 292.34%1.91B | -79.46%487.62M | 138.24%2.37B | --996.35M |
| Net cash flow | ||||
| Beginning cash position | 9.19%4.52B | 62.50%4.14B | 37.56%2.55B | --1.85B |
| Current changes in cash | 171.97%1.03B | -76.11%380.44M | 128.90%1.59B | --695.7M |
| End cash Position | 22.89%5.56B | 9.19%4.52B | 62.50%4.14B | --2.55B |
| Free cash flow | -714.62%-873.08M | 86.21%-107.18M | -158.49%-777.14M | ---300.65M |
| Currency Unit | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |